The main differences between bipolar 1 and bipolar 2 are the severity of manic episodes, and whether or not someone ...

Bipolar disorder affects about 4% of the US population and causes symptoms like depression, fatigue, impulsivity, and periods of high energy.

The approval is supported by a combination of current clinical data and model-informed drug development techniques.

The Walsh Research Institute (WRI) announces a major scientific breakthrough in understanding bipolar disorder, revealed in The Essence of Bipolar Disorder by William J. Walsh, Ph.D. (Skyhorse ...

Paris: The FDA has approved UZEDY, the first subcutaneous long-acting risperidone formulation utilizing SteadyTeq™ technology ...

This is a developing news story. Please check back soon for updates. The FDA approved extended-release Uzedy for the ...

After single-blind placebo run-in periods of ≤7 days, patients were randomly assigned to 3 weeks of sublingual asenapine (10 mg twice daily [BID] on day 1, flexible-dose 5 or 10 mg BID thereafter), ...

Bipolar disorder is a mental health condition characterized by extreme mood swings, including periods of mania (elevated mood ...

FDA approves UZEDY® (risperidone) extended-release injectable suspension for subcutaneous use as monotherapy or as adjunctive ...

The FDA expanded the approval of once-monthly risperidone (Uzedy) to include adjunct treatment for bipolar I disorder, ...